Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 480

1.

Autoradiographic analysis of internal plutonium radiation exposure in Nagasaki atomic bomb victims.

Shichijo K, Takatsuji T, Fukumoto M, Nakashima M, Matsuyama MM, Sekine I.

Heliyon. 2018 Jun 29;4(6):e00666. doi: 10.1016/j.heliyon.2018.e00666. eCollection 2018 Jun.

2.

Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells.

Qin Y, Sekine I, Fan M, Takiguchi Y, Tada Y, Shingyoji M, Hanazono M, Yamaguchi N, Tagawa M.

Cancer Cell Int. 2017 Dec 11;17:120. doi: 10.1186/s12935-017-0493-8. eCollection 2017.

3.

Fish hook injury: an easy removal using the string yank technique.

Watari T, Sekine I, Tokuda Y.

BMJ Case Rep. 2017 Nov 27;2017. pii: bcr-2017-222987. doi: 10.1136/bcr-2017-222987. No abstract available.

PMID:
29183899
4.

An image cytometric technique is a concise method to detect adenoviruses and host cell proteins and to monitor the infection and cellular responses induced.

Morinaga T, Nguyễn TTT, Zhong B, Hanazono M, Shingyoji M, Sekine I, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M.

Virol J. 2017 Nov 10;14(1):219. doi: 10.1186/s12985-017-0888-0.

5.

Immune checkpoint inhibitor-related myocarditis.

Tajiri K, Aonuma K, Sekine I.

Jpn J Clin Oncol. 2018 Jan 1;48(1):7-12. doi: 10.1093/jjco/hyx154. Review.

PMID:
29045749
6.

Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes.

Yamauchi S, Zhong B, Kawamura K, Yang S, Kubo S, Shingyoji M, Sekine I, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M.

BMC Cancer. 2017 Sep 5;17(1):622. doi: 10.1186/s12885-017-3621-x.

7.

Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia.

Tachi H, Shiozawa T, Sakai C, Kasuga M, Nakazawa K, Morishima Y, Satoh H, Hizawa N, Sakashita S, Sekine I.

J Thorac Oncol. 2017 Aug;12(8):e118-e120. doi: 10.1016/j.jtho.2017.03.022. No abstract available.

PMID:
28748819
8.

Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).

Sekine I, Harada H, Yamamoto N, Wakabayashi M, Murakami H, Goto K, Nogami N, Seto T, Oshita F, Okamoto H, Tanaka H, Tamura T, Ishikura S, Ohe Y.

Lung Cancer. 2017 Jun;108:232-237. doi: 10.1016/j.lungcan.2017.04.002. Epub 2017 Apr 4.

PMID:
28625642
9.

What is the optimal first-line treatment for advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer?

Sekine I.

J Thorac Dis. 2017 May;9(5):E447-E450. doi: 10.21037/jtd.2017.04.43. No abstract available.

10.

Cardiovascular toxic effects of targeted cancer therapy.

Tajiri K, Aonuma K, Sekine I.

Jpn J Clin Oncol. 2017 Sep 1;47(9):779-785. doi: 10.1093/jjco/hyx071. Review.

PMID:
28531278
11.

Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients.

Tajiri K, Aonuma K, Sekine I.

Jpn J Clin Oncol. 2017 Aug 1;47(8):678-682. doi: 10.1093/jjco/hyx068. Review.

PMID:
28505345
12.

Azathioprine combination therapy for steroid-refractory hepatic immune system-related adverse events.

Iwamoto K, Ishitsuka Y, Tanaka R, Sekine I, Fujimoto M.

Eur J Dermatol. 2017 Jun 1;27(3):301-303. doi: 10.1684/ejd.2017.2973. No abstract available.

PMID:
28468733
13.

Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.

Shimazu K, Tada Y, Morinaga T, Shingyoji M, Sekine I, Shimada H, Hiroshima K, Namiki T, Tatsumi K, Tagawa M.

BMC Cancer. 2017 May 2;17(1):309. doi: 10.1186/s12885-017-3300-y.

14.

Myositis Ossificans of the Hip Due to Pyogenic Arthritis Caused by Campylobacter fetus Subspecies fetus.

Nishiguchi S, Sekine I, Kuroda S, Sato M, Kitagawa I.

Intern Med. 2017;56(8):967-972. doi: 10.2169/internalmedicine.56.7906. Epub 2017 Apr 15.

15.

Potential Activity of Amrubicin as a Salvage Therapy for Merkel Cell Carcinoma.

Sakaida E, Ebata T, Iwasawa S, Kurimoto R, Yonemori S, Ota S, Nakatani Y, Sekine I, Takiguchi Y.

Intern Med. 2017;56(5):567-570. doi: 10.2169/internalmedicine.56.7675. Epub 2017 Mar 1.

16.

Case reports of adverse drug reactions associated with nivolumab administration.

Sekine I.

Jpn J Clin Oncol. 2017 Mar 1;47(3):193. doi: 10.1093/jjco/hyx014. No abstract available.

PMID:
28204538
17.

Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab.

Tanaka R, Fujisawa Y, Sae I, Maruyama H, Ito S, Hasegawa N, Sekine I, Fujimoto M.

Jpn J Clin Oncol. 2017 Feb 11;47(2):175-178. doi: 10.1093/jjco/hyw167.

PMID:
28173241
18.

Retrospective analysis of lung cancer patients treated with supportive care alone.

Ashinuma H, Shingyoji M, Yoshida Y, Itakura M, Iizasa T, Sakashita Y, Sekine I.

Int J Clin Oncol. 2017 Jun;22(3):455-460. doi: 10.1007/s10147-017-1094-1. Epub 2017 Jan 31.

PMID:
28144883
19.

Are there any differences in genomic characterization of non-small cell lung cancer between African Americans and Whites?

Sekine I.

J Thorac Dis. 2016 Nov;8(11):E1517-E1519. doi: 10.21037/jtd.2016.11.65. No abstract available.

20.

Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology.

Shibata H, Kato S, Sekine I, Abe K, Araki N, Iguchi H, Izumi T, Inaba Y, Osaka I, Kato S, Kawai A, Kinuya S, Kodaira M, Kobayashi E, Kobayashi T, Sato J, Shinohara N, Takahashi S, Takamatsu Y, Takayama K, Takayama K, Tateishi U, Nagakura H, Hosaka M, Morioka H, Moriya T, Yuasa T, Yurikusa T, Yomiya K, Yoshida M.

ESMO Open. 2016 Mar 16;1(2):e000037. eCollection 2016. Review.

21.

Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report.

Fujita K, Morishima Y, Aida Y, Tsunoda Y, Hida N, Shiozawa T, Nakazawa K, Sekine I, Hizawa N.

J Thorac Oncol. 2017 Feb;12(2):e11-e13. doi: 10.1016/j.jtho.2016.10.011. Epub 2016 Oct 22. No abstract available.

22.

Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma.

Jiang Y, Zhong B, Kawamura K, Morinaga T, Shingyoji M, Sekine I, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M.

BMC Cancer. 2016 Jul 12;16:455. doi: 10.1186/s12885-016-2483-y.

23.

Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report.

Tanaka R, Maruyama H, Tomidokoro Y, Yanagiha K, Hirabayashi T, Ishii A, Okune M, Inoue S, Sekine I, Tamaoka A, Fujimoto M.

Jpn J Clin Oncol. 2016 Sep;46(9):875-8. doi: 10.1093/jjco/hyw090. Epub 2016 Jul 5.

PMID:
27380808
24.

Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.

Kubota K, Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T.

Support Care Cancer. 2016 Sep;24(9):4025-33. doi: 10.1007/s00520-016-3203-5. Epub 2016 Apr 29.

25.

An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol.

Tada Y, Hiroshima K, Shimada H, Shingyoji M, Suzuki T, Umezawa H, Sekine I, Takiguchi Y, Tatsumi K, Tagawa M.

Springerplus. 2016 Feb 27;5:195. doi: 10.1186/s40064-016-1893-2. eCollection 2016.

26.

Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.

Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I, Tada Y, Tatsumi K, Koide S, Iwama A, Takiguchi Y.

Int J Oncol. 2016 May;48(5):1825-36. doi: 10.3892/ijo.2016.3419. Epub 2016 Mar 4.

27.

Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.

Sakaida E, Iwasawa S, Kurimoto R, Ebata T, Imai C, Oku T, Sekine I, Tada Y, Tatsumi K, Takiguchi Y.

Jpn J Clin Oncol. 2016 Apr;46(4):370-7. doi: 10.1093/jjco/hyv203. Epub 2016 Jan 10.

28.

Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer.

Sekine I, Sumi M, Satouchi M, Tsujino K, Nishio M, Kozuka T, Niho S, Nihei K, Yamamoto N, Harada H, Ishikura S, Tamura T.

Cancer Sci. 2016 Mar;107(3):315-9. doi: 10.1111/cas.12875. Epub 2016 Feb 19.

29.

The Nagasaki Atomic Bomb Survivors' Tumor Tissue Bank.

Miura S, Akazawa Y, Kurashige T, Tukasaki K, Kondo H, Yokota K, Mine M, Miyazaki Y, Sekine I, Nakashima M.

Lancet. 2015 Oct 31;386(10005):1738. doi: 10.1016/S0140-6736(15)00698-4. No abstract available.

PMID:
26545440
30.

Replication-competent adenoviruses with the type 35-derived fiber-knob region achieve reactive oxygen species-dependent cytotoxicity and produce greater toxicity than those with the type 5-derived region in pancreatic carcinoma.

Yamauchi S, Kawamura K, Okamoto S, Morinaga T, Jiang Y, Shingyoji M, Sekine I, Kubo S, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M.

Apoptosis. 2015 Dec;20(12):1587-98. doi: 10.1007/s10495-015-1171-8.

PMID:
26373551
31.

[Targeted therapy for solid tumors in the elderly].

Ashinuma H, Sekine I.

Nihon Rinsho. 2015 Aug;73(8):1419-24. Japanese.

PMID:
26281699
32.

Expression of p53 synergistically augments caspases-mediated apoptosis induced by replication-competent adenoviruses in pancreatic carcinoma cells.

Takei Y, Okamoto S, Kawamura K, Jiang Y, Morinaga T, Shingyoji M, Sekine I, Kubo S, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Yamaguchi N, Tagawa M.

Cancer Gene Ther. 2015 Sep;22(9):445-53. doi: 10.1038/cgt.2015.33. Epub 2015 Aug 7.

PMID:
26251031
33.

Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer.

Asao T, Nokihara H, Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Yamamoto N, Sekine I, Kunitoh H, Fujiwara Y, Ohe Y.

Jpn J Clin Oncol. 2015 Oct;45(10):941-6. doi: 10.1093/jjco/hyv107. Epub 2015 Jul 31.

PMID:
26232449
34.

A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene.

Tada Y, Hiroshima K, Shimada H, Morishita N, Shirakawa T, Matsumoto K, Shingyoji M, Sekine I, Tatsumi K, Tagawa M.

Springerplus. 2015 Jul 16;4:358. doi: 10.1186/s40064-015-1123-3. eCollection 2015.

35.

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.

Kanda S, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Kubota K, Tamura T, Ohe Y.

Lung Cancer. 2015 Sep;89(3):287-93. doi: 10.1016/j.lungcan.2015.06.016. Epub 2015 Jul 2.

PMID:
26169499
36.

Cytotoxic effects of replication-competent adenoviruses on human esophageal carcinoma are enhanced by forced p53 expression.

Yang S, Kawamura K, Okamoto S, Yamauchi S, Shingyoji M, Sekine I, Kobayashi H, Tada Y, Tatsumi K, Hiroshima K, Shimada H, Tagawa M.

BMC Cancer. 2015 Jun 10;15:464. doi: 10.1186/s12885-015-1482-8.

37.

A combinatory use of adenoviruses expressing melanoma differentiation-associated gene-7 and replication-competent adenoviruses produces synergistic effects on pancreatic carcinoma cells.

Ma G, Zhong B, Okamoto S, Jiang Y, Kawamura K, Liu H, Li Q, Shingyoji M, Sekine I, Tada Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M.

Tumour Biol. 2015 Sep;36(10):8137-45. doi: 10.1007/s13277-015-3555-3. Epub 2015 May 20.

PMID:
25990458
38.

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.

Horinouchi H, Yamamoto N, Fujiwara Y, Sekine I, Nokihara H, Kubota K, Kanda S, Yagishita S, Wakui H, Kitazono S, Mizugaki H, Tokudome T, Tamura T.

Invest New Drugs. 2015 Aug;33(4):881-9. doi: 10.1007/s10637-015-0243-5. Epub 2015 May 1.

39.

Alveolar hemorrhage associated with pemetrexed administration.

Kurimoto R, Sekine I, Iwasawa S, Sakaida E, Tada Y, Tatsumi K, Takahashi Y, Nakatani Y, Imai C, Takiguchi Y.

Intern Med. 2015;54(7):833-6. doi: 10.2169/internalmedicine.54.3414. Epub 2015 Apr 1.

40.

Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions.

Okamoto S, Jiang Y, Kawamura K, Shingyoji M, Tada Y, Sekine I, Takiguchi Y, Tatsumi K, Kobayashi H, Shimada H, Hiroshima K, Tagawa M.

Cell Death Dis. 2014 Nov 13;5:e1517. doi: 10.1038/cddis.2014.475.

41.

Chronic obstructive pulmonary disease as a risk factor for lung cancer.

Takiguchi Y, Sekine I, Iwasawa S, Kurimoto R, Tatsumi K.

World J Clin Oncol. 2014 Oct 10;5(4):660-6. doi: 10.5306/wjco.v5.i4.660. Review.

42.

Clinical characteristics and functional assessment of elderly patients with cancer.

Sekine I.

Rinsho Ketsueki. 2014 May;55(5):518-25. Review. Japanese. No abstract available.

PMID:
24881916
43.

Stereotactic radiosurgery for patients with brain metastases.

Takiguchi Y, Sekine I, Iwasawa S, Kurimoto R, Uehara T.

Lancet Oncol. 2014 Jun;15(7):e247-8. doi: 10.1016/S1470-2045(14)70182-2. No abstract available.

PMID:
24872103
44.

Current status of medical oncology in Japan--reality gleaned from a questionnaire sent to designated cancer care hospitals.

Takiguchi Y, Sekine I, Iwasawa S, Kurimoto R, Sakaida E, Tamura K.

Jpn J Clin Oncol. 2014 Jul;44(7):632-40. doi: 10.1093/jjco/hyu059. Epub 2014 May 12.

PMID:
24821975
45.

A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).

Kenmotsu H, Niho S, Ito T, Ishikawa Y, Noguchi M, Tada H, Sekine I, Watanabe S, Yoshimura M, Yamamoto N, Oshita F, Kubota K, Nagai K.

Lung Cancer. 2014 Jun;84(3):254-8. doi: 10.1016/j.lungcan.2014.03.007. Epub 2014 Mar 13.

PMID:
24679951
46.

Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin in Japanese Patients With Locally Advanced Nonsquamous Non-Small Cell Lung Cancer: A Post Hoc Analysis of Survival and Recurrent Sites.

Niho S, Nokihara H, Nihei K, Akimoto T, Sumi M, Ito Y, Yoh K, Goto K, Ohmatsu H, Horinouchi H, Yamamoto N, Sekine I, Kubota K, Ohe Y, Tamura T.

Am J Clin Oncol. 2016 Apr;39(2):132-5. doi: 10.1097/COC.0000000000000030.

PMID:
24441582
47.

A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer.

Sekine I, Okamoto H, Horai T, Nakagawa K, Ohmatsu H, Yokoyama A, Katakami N, Shibuya M, Saijo N, Fukuoka M.

Clin Lung Cancer. 2014 Mar;15(2):96-102. doi: 10.1016/j.cllc.2013.11.006. Epub 2013 Nov 14.

PMID:
24361248
48.

Incidence, risk factors and treatment outcomes of extravasation of cytotoxic agents in an outpatient chemotherapy clinic.

Sakaida E, Sekine I, Iwasawa S, Kurimoto R, Uehara T, Ooka Y, Akanuma N, Tada Y, Imai C, Oku T, Takiguchi Y.

Jpn J Clin Oncol. 2014 Feb;44(2):168-71. doi: 10.1093/jjco/hyt186. Epub 2013 Dec 2.

PMID:
24302758
49.

Overdiagnosis in lung cancer screening with low-dose computed tomography.

Takiguchi Y, Sekine I, Iwasawa S.

J Thorac Oncol. 2013 Nov;8(11):e101-2. doi: 10.1097/JTO.0b013e3182a476d4. No abstract available.

50.

Choroidal metastasis of non-small cell lung cancer that responded to gefitinib.

Shimomura I, Tada Y, Miura G, Suzuki T, Matsumura T, Tsushima K, Terada J, Kurimoto R, Sakaida E, Sekine I, Takiguchi Y, Yamamoto S, Tatsumi K.

Case Rep Ophthalmol Med. 2013;2013:213124. doi: 10.1155/2013/213124. Epub 2013 Sep 12.

Supplemental Content

Loading ...
Support Center